Skip to main
CAH

Cardinal Health (CAH) Stock Forecast & Price Target

Cardinal Health (CAH) Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 33%
Buy 58%
Hold 8%
Sell 0%
Strong Sell 0%

Bulls say

Cardinal Health is a strong contender in the US pharmaceutical market with a focus on specialty and biopharma products and services. Despite recent stock decreases, the company's diverse revenue streams, strong balance sheet, and investments in technology and infrastructure position them well for success in the evolving healthcare industry. However, potential challenges such as changes in reimbursement rates and pricing models may impact their growth, but their partnerships and advanced logistics capabilities give them a competitive advantage. With their expansion into specialty care and technology-enabled solutions, Cardinal Health is set for continued growth and success in the future.

Bears say

Cardinal Health is a leading pharmaceutical wholesaler in the US with a highly competitive industry, which could pressure margins in the core drug distribution business. Additionally, the expected increase in volumes due to the current wave of drug patent expirations and the positive impact from generics are expected to taper off significantly over the next several years. This, along with sustainability concerns around high growth in the biotech sector and potential risks associated with the drug distribution space, could have a negative impact on Cardinal Health's stock performance.

Cardinal Health (CAH) has been analyzed by 12 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 58% recommend Buy, 8% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Cardinal Health and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Cardinal Health (CAH) Forecast

Analysts have given Cardinal Health (CAH) a Buy based on their latest research and market trends.

According to 12 analysts, Cardinal Health (CAH) has a Buy consensus rating as of May 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $228.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $228.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Cardinal Health (CAH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.